Characteristics of hepatitis B core antibody level in the natural history of chronic hepatitis B

Discov Med. 2018 Oct;26(143):119-125.

Abstract

Objective: We aimed to analyze serum antibody to hepatitis B core antigen (anti-HBc) level during different immunological phases in the natural history of patients with chronic hepatitis B (CHB).

Methods: Serum anti-HBc levels in the immune tolerant (IT), immune clearance (IC), low replicative (LR), and HBeAg negative hepatitis (ENH) phases from 634 treatment-naïve CHB patients were measured and compared between phases and with other serum markers.

Results: Median serum anti-HBc levels were different between the phases of CHB. Serum anti-HBc level was highest in the ENH phase and lowest in the IT phase. Serum anti-HBc level correlated only with ALT in the IC phase (r = 0.248, p < 0.001). The area under the receiver operating characteristic curve (AUC) of anti-HBc at a cutoff value of 9.03 S/CO for differentiation of IT and IC phases was 0.689 (sensitivity 74.03%, specificity 60.23%). The AUC for differentiation of LR and ENH phases was 0.751 (sensitivity 68.32%, specificity 70.53%) at a cutoff value of 9.74 S/CO for anti-HBc.

Conclusions: Serum anti-HBc levels were significantly different across different phases of CHB and were associated with hepatitis activities.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Biomarkers / blood
  • Disease Progression
  • Female
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Core Antigens / immunology*
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / blood*
  • Hepatitis B, Chronic / diagnosis*
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / pathology
  • Humans
  • Male
  • Middle Aged
  • Sustained Virologic Response
  • Viral Load

Substances

  • Antiviral Agents
  • Biomarkers
  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens